Bengaluru, July 14 -- The shares of one of India's leading API manufacturers, engaged in the production and export of APIs, intermediates, and nutraceutical ingredients, were under pressure and declined 4% after a key product in its custom synthesis portfolio faced a potential earnings risk.

With a market capitalization of Rs 1,78,634 Crores, the share price of Divis Laboratories Ltd was trading over 4% down to hit an intraday low of Rs 6547.50 per share from its previous day closing price of Rs 6833.10 per share.

Reason For the Crash Divi's Laboratories is facing a potential earnings setback after Indian drugmaker MSN won a patent litigation case related to Entresto, a blockbuster heart failure drug marketed by Novartis. The ruling al...